Reuters
Published Jun 19, 2017 02:50PM ET
Updated Jun 19, 2017 03:01PM ET
Supreme Court again limits where companies can be sued
By Andrew Chung
WASHINGTON (Reuters) - The Supreme Court on Monday slapped limits on where injury lawsuits may be filed for the second time in three weeks, again siding with businesses that want to prevent plaintiffs from "shopping" for friendly courts for their cases.
In an 8-1 ruling, the justices overturned a lower court's decision that had allowed hundreds of out-of-state patients who took Bristol-Myers Squibb Co's (N:BMY) blood-thinning medication Plavix to sue the company in California.
State courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there, the justices ruled.
The Supreme Court on May 30 reached a similar conclusion in a separate case involving out-of-state injury claims against Texas-based BNSF Railway Co
Businesses and plaintiffs are engaged in a battle over where lawsuits seeking financial compensation for injuries can be filed.
Companies typically can be sued in a state where they are headquartered or incorporated, as well as where they have important ties. Businesses want to limit the ability of plaintiffs to shop for courts in states with laws conducive to such injury lawsuits.
Plaintiffs contend that corporations are seeking to squeeze their access to compensation for injuries by denying them their day in state courts.
The underlying lawsuits filed in 2012 against Bristol-Myers and California-based drug distributor McKesson Corp (NYSE:MCK) involved 86 California residents and 575 non-Californians, alleging Plavix increased their risk of stroke, heart attack and internal bleeding.
Bristol-Myers argued it should not face claims in California by plaintiffs who do not live in the state. The company is incorporated in Delaware and headquartered in New York.
The California Supreme Court ruled in August 2016 that it could preside over the case because Bristol-Myers conducted a national marketing campaign and sold nearly $1 billion of the drug in the state.
Writing for the Supreme Court majority on Monday, Justice Samuel Alito said the California court was wrong to rule that it could hear the case "without identifying any adequate link between the state and the nonresidents' claim."
In a dissenting opinion, Justice Sonia Sotomayor predicted that the Supreme Court's ruling will make it harder to consolidate lawsuits against corporations in state courts and lead to unfairness for individual injury plaintiffs.
There "is nothing unfair about subjecting a massive corporation to suit in a state for a nationwide course of conduct that injures" state residents and nonresidents alike, Sotomayor wrote.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.